OMERS ADMINISTRATION Corp Lowers Stock Holdings in Climb Bio, Inc. $CLYM

OMERS ADMINISTRATION Corp cut its position in Climb Bio, Inc. (NASDAQ:CLYM) by 80.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,700 shares of the company’s stock after selling 68,766 shares during the quarter. OMERS ADMINISTRATION Corp’s holdings in Climb Bio were worth $114,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Dimensional Fund Advisors LP acquired a new position in Climb Bio during the 1st quarter worth about $715,000. Hsbc Holdings PLC boosted its holdings in Climb Bio by 107.2% during the 4th quarter. Hsbc Holdings PLC now owns 24,744 shares of the company’s stock valued at $99,000 after acquiring an additional 12,800 shares during the period. Seven Fleet Capital Management LP acquired a new position in Climb Bio in the 4th quarter valued at about $306,000. Virtu Financial LLC acquired a new position in Climb Bio in the 4th quarter valued at about $43,000. Finally, XTX Topco Ltd increased its stake in Climb Bio by 19.4% during the fourth quarter. XTX Topco Ltd now owns 34,852 shares of the company’s stock worth $139,000 after purchasing an additional 5,668 shares during the period. Hedge funds and other institutional investors own 69.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on CLYM shares. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Climb Bio in a research report on Wednesday, June 24th. BTIG Research lifted their price objective on shares of Climb Bio from $19.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, June 11th. Wedbush upped their target price on shares of Climb Bio from $17.00 to $20.00 and gave the stock an “outperform” rating in a research note on Monday, July 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Climb Bio in a report on Friday, July 17th. Finally, Guggenheim assumed coverage on shares of Climb Bio in a research report on Monday, June 8th. They issued a “buy” rating and a $35.00 price target for the company. Three investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $22.00.

Climb Bio Price Performance

CLYM opened at $11.90 on Friday. The business has a fifty day moving average price of $12.20 and a 200 day moving average price of $8.99. Climb Bio, Inc. has a 12 month low of $1.36 and a 12 month high of $14.41. The stock has a market capitalization of $681.39 million, a price-to-earnings ratio of -15.26 and a beta of 0.07.

Climb Bio (NASDAQ:CLYM) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.06. On average, research analysts anticipate that Climb Bio, Inc. will post -0.87 earnings per share for the current year.

Climb Bio Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.